Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII) -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (243)	1/29/1998 5:31:00 PM
From: Peter Silsbee	Read Replies (1) \| Respond to of 1494

Another trial result: Neurobiological Technologies, Inc. Announces Publication of Phase I/II Xerecept(TM)Trial Results biz.yahoo.com Finally some positive CRF results! Though it's hard to get too excited about statements like "the data suggest that Xerecept has the potential to be at least as effective as the current standard treatment for the condition." I know, they have to sound wishy-washy so they don't get sued... Larger Phase I/II study is already in progress. PLS

To: Cacaito who wrote (243)	1/29/1998 10:49:00 PM
From: NeuroInvestment	Read Replies (3) \| Respond to of 1494

It was in fact a p value of .10; i.e. a 10% statistical likelihood that the trends towards efficacy noted were due to chance, not drug action. I am generally sympathetic to more liberal statistics; the use of .05 as the criterion of 'significance' is arbitrary ('the tyranny of .05)....and there have been suggestions (regarding Myotrophin) that .10 is a reasonable criterion in disorders where there is a lack of effective treatment (a suggestion the FDA has rejected). With the small sample size, this effect may be meaningful. Having said that, I think it was a PR mistake for the Company to fudge on this...if they wanted to make a case for an expanded definition of 'significance', they should have said so. However, in the long run, the only arbiters that will matter on this trial are the pharmaceutical companies Paul Freiman is trying to cut a deal with by the end of business tomorrow....and they understand .05, .10, and the limitations of each. NeuroInvestment